Aarti Drugs Limited reports ₹82.77 crore Q2 PAT, ₹826.24 crore revenue

Aarti Drugs Limited reported consolidated revenue of ₹826.24 crore and profit after tax of ₹82.77 crore for the quarter ended September 30, 2026, while its first-half PAT reached ₹132.90 crore. The result is relevant because it provides the latest consolidated profit and revenue position for the pharmaceutical manufacturer during FY27.

What did Aarti Drugs report for the September 2026 quarter?

Aarti Drugs reported consolidated revenue of ₹826.24 crore and consolidated PAT of ₹82.77 crore for Q2 FY27. The quarter covered the three months ended September 30, 2026, and forms part of the company’s first-half financial performance for FY27.

For the six months ended September 30, 2026, the company reported PAT of ₹132.90 crore. This means the September quarter accounted for a substantial part of the first-half profit disclosed in the results summary. The supplied information does not provide a comparable year-earlier Q2 profit or revenue figure alongside these consolidated results, so a year-on-year comparison cannot be calculated from the available data.

The numbers are reported on a consolidated basis, which includes the financial performance of Aarti Drugs and its subsidiaries. Consolidated results can differ from the standalone performance of the listed parent because they incorporate subsidiary income, expenses, assets and liabilities.

What are the key Q2 and H1 FY27 financial figures?

The key disclosed figures are ₹826.24 crore of Q2 consolidated revenue, ₹82.77 crore of Q2 consolidated PAT and ₹132.90 crore of H1 consolidated PAT. All figures below have been presented in crore for consistency.

The results also recorded a ₹2.09 crore write-off relating to capital work-in-progress, or CWIP. CWIP generally represents spending on projects or assets that are not yet ready for intended use. The disclosed write-off is a charge recorded in the financial statements and is therefore relevant when assessing the quarter’s reported profitability.

Aarti Drugs had scheduled a board meeting on November 3, 2026, to consider, approve and take on record audited financial results for the quarter and half year ended September 30, 2026. The company also informed exchanges on October 28, 2026 about an earnings conference call related to the Q2 and H1 FY27 results.

What accounting matters were disclosed in the results?

Aarti Drugs disclosed that a foreign subsidiary reported a loss based on management-certified financial results. The available information does not identify the subsidiary or quantify the loss, but the disclosure indicates that this subsidiary’s result was included in the consolidated financial reporting process.

Management-certified results are financial information prepared and certified by a company’s management. Investors generally review such disclosures alongside the consolidated results and the notes to accounts, particularly where a subsidiary’s performance has affected group profitability.

The CWIP write-off is the other specific accounting item stated in the available results information. No project name, asset category or reason for the write-off has been provided in the supplied material. As a result, the disclosed amount can be noted, but its operational cause cannot be assessed from the available information.

How does the latest quarter compare with Aarti Drugs' recent financial record?

Aarti Drugs' FY26 financial data showed revenue of ₹2,260.39 crore and net profit of ₹169.22 crore, compared with revenue of ₹2,173.65 crore and net profit of ₹157.31 crore in FY25. The historical figures provide context for the company’s scale before the latest FY27 half-year update.

The same FY26 data showed return on equity of 10.58%, against 9.83% in FY25. Revenue and net profit are annual figures, whereas the latest disclosure covers a single quarter and the first half of FY27. They should therefore not be treated as directly comparable without complete corresponding period data.

Separately, historical quarterly data for the quarter ended September 2025 showed sales of ₹578.95 crore and operating profit of ₹75.19 crore. That table is distinct from the latest consolidated Q2 FY27 figures and does not provide sufficient detail to establish a like-for-like comparison between reporting bases or periods.

How do the Q2 figures matter for investors and operations?

The reported ₹826.24 crore quarterly revenue establishes the current consolidated revenue base disclosed for Aarti Drugs in Q2 FY27. The ₹82.77 crore PAT figure shows the profit available after expenses, finance costs, taxes and other reported items at the consolidated level, including the stated CWIP write-off.

For investors, the results place attention on the composition of the first-half PAT of ₹132.90 crore, the subsidiary loss disclosure and management’s discussion during the scheduled earnings call. The available data does not provide segment-wise sales, margin details, cash flow, debt data or an outlook, so conclusions on product-level demand or future earnings cannot be drawn from these figures alone.

For the wider pharmaceutical and chemical manufacturing value chain, the result is a current data point from a listed manufacturer with consolidated operations. However, the disclosed information does not specify changes in capacity, customer orders, pricing, export volumes or workforce, and no conclusions on those areas are supported by the supplied results.

Conclusion

Aarti Drugs reported consolidated Q2 FY27 revenue of ₹826.24 crore and PAT of ₹82.77 crore, taking its H1 PAT to ₹132.90 crore. The reported quarter also included a ₹2.09 crore CWIP write-off and a loss at one foreign subsidiary based on management-certified results, both of which are relevant to reading the consolidated outcome.

Investors will watch for the company’s audited results record, the earnings conference call and any further detail on the CWIP write-off and foreign subsidiary performance. Additional disclosures on margins, operating conditions and the subsidiary loss would provide a fuller basis for assessing the first-half performance.